ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the founder and chairman of ImmunueOnco, Dr. Tian, Wenzhi, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024 and deliver a speech at the Biotech Showcase™ held at the same time, comprehensively demonstrate ImmuneOnco’s innovative product pipeline and progress in clinical research and development.

On October 27, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that 2 drug candidates independently developed by the company, IMM2510, a bispecific antibody-receptor recombinant protein targeting PD-L1/VEGFA and IMM27M, an ADCC-enhanced CTLA-4 monoclonal antibody, are proposed to combined for the treatment of advanced solid tumors.

On October 16, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the company's independently developed humanized IgG1 CD24 antibody(Project number: IMM47) was approved by the National Medical Products Administration (NMPA) for clinical trials.

Recently, the R&D team of ImmuneOnco (Hong Kong Stock Exchange stock code: 01541.HK) reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".

(Hong Kong, September 5th, 2023) ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).